Available for Android and iOS devices. CYP 2D6 is subject to genetic polymorphism (about 6%–8% of Caucasians, and a very low percentage of Asians, have little or no activity and are "poor metabolizers") and to inhibition by a variety of substrates and some non-substrates, notably quinidine. Risperdal Consta injection is sometimes given with lithium or valproate (Depakene). The most common adverse reactions in the double-blind, placebo-controlled periods of the bipolar disorder trials were weight increased (5% in the monotherapy trial) and tremor and parkinsonism (≥ 10% in the adjunctive treatment trial).The most common adverse reactions that were associated with discontinuation from the 12-week double-blind, placebo-controlled trial in patients with schizophrenia (causing discontinuation in ≥1% of patients) were agitation, depression, anxiety, and akathisia. Risperidone injection is used to treat the symptoms of psychotic (mental) disorders, such as schizophrenia. While all of the drugs in the class have been shown to produce some metabolic changes, each drug has its own specific risk profile.Hyperglycemia and diabetes mellitus, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, have been reported in patients treated with atypical antipsychotics including RISPERDALPatients with an established diagnosis of diabetes mellitus who are started on atypical antipsychotics, including RISPERDALPooled data from 3 double-blind, placebo-controlled studies in subjects with schizophrenia and 4 double-blind, placebo-controlled monotherapy studies in subjects with bipolar mania with oral risperidone are presented in Table 1.In longer-term, controlled and uncontrolled studies in adult subjects, RISPERDALUndesirable alterations in lipids have been observed in patients treated with atypical antipsychotics.Pooled data from 7 placebo-controlled, 3- to 8- week, fixed- or flexible-dose studies in adult subjects with schizophrenia or bipolar mania are presented in Table 2.In longer-term, controlled and uncontrolled studies, RISPERDALWeight gain has been observed with atypical antipsychotic use. WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSISElderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. In one peri/post-natal development study, there was an increase in stillborn rat pups at a dose of 2.5 mg/kg or 1.5 times the oral MRHD on a mg/mPlacental transfer of risperidone occurs in rat pups. The possibility of multiple drug involvement should be considered.

Risperdal Consta wird vom medizinischen Fachpersonal verabreicht und alle zwei Wochen als intramuskuläre Injektion entweder in den Arm oder in das Gesäß gegeben. After the sixth injection (Week 10), investigator ratings indicated that 1% of patients treated with 25 mg or 50 mg Risperdal ConstaIn a separate study to observe local-site tolerability in which Risperdal ConstaThe following adverse reactions have been identified during postapproval use of risperidone; because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency: agranulocytosis, alopecia, anaphylactic reaction, angioedema, atrial fibrillation, blood cholesterol increased, blood triglycerides increased, diabetes mellitus, diabetic ketoacidosis in patients with impaired glucose metabolism, drug withdrawal syndrome neonatal, dysgeusia, hypoglycemia, hypothermia, ileus, inappropriate antidiuretic hormone secretion, intestinal obstruction, jaundice, mania, pancreatitis, priapism, QT prolongation, sleep apnea syndrome, thrombocytopenia, urinary retention, and water intoxication.

Alternatively, a starting … The clinical effects of this dose adjustment should not be anticipated earlier than 3 weeks after the first injection with the higher dose.In patients with clinical factors such as hepatic or renal impairment or certain drug interactions that increase risperidone plasma concentrations Do not combine two different dose strengths of Risperdal ConstaPatients with renal or hepatic impairment should be treated with titrated doses of oral RISPERDALPatients with renal impairment may have less ability to eliminate risperidone than normal adults.

There is no general agreement about specific pharmacological treatment regimens for uncomplicated NMS.If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. When restarting patients who have had an interval off treatment with Risperdal ConstaThere are no systematically collected data to specifically address switching patients from other antipsychotics to Risperdal ConstaCo-administration of carbamazepine and other CYP 3A4 enzyme inducers (e.g., phenytoin, rifampin, phenobarbital) with risperidone would be expected to cause decreases in the plasma concentrations of the sum of risperidone and 9-hydroxyrisperidone combined, which could lead to decreased efficacy of Risperdal ConstaFluoxetine and paroxetine, CYP 2D6 inhibitors, have been shown to increase the plasma concentration of risperidone 2.5–2.8 fold and 3–9 fold respectively. The most common injection site reactions (≥ 5%) were injection site pain and erythema. It works by changing the effects of chemicals in the brain. An increase of mortality in elderly patients with dementia-related psychosis was seen with the use of oral risperidone regardless of concomitant use with furosemide.

Hold base of vial and pull up on the sterile blister to remove.Attach the syringe to the vial adapter with a firm Inject entire amount of diluent from syringe into the vial.Immediately proceed to the next step so suspension does not settle.Invert vial completely.